et al. Cyclosporine in dermatology. J Am Acad Dermatol 1989: 21: 1245–1256.
et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002: 109: 547–555.DOI: 10.1067/mai.2002.121832
et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002: 109: 539–546.DOI: 10.1067/mai.2002.121831
Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacological effects. Allergy Asthma Proc 2002: 23: 191–197.
et al. Topical cyclosporine and psoriasis (letter). Lancet 1987: i: 806.DOI: 10.1016/S0140-6736(87)92829-7
Tacrolimus (FK 506) – a new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992: 128: 781–785.DOI: 10.1001/archderm.128.6.781
, , , , ,
European FK 506 Multicenter Psoriasis Study Group. Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996: 132: 419–423.DOI: 10.1001/archderm.132.4.419
Entstehungsgeschichte und präklinisches Profil von Pimecrolimus. Hautarzt 2003: 54: 405–412.
Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis. Drugs 2002: 62: 817–840.
Elidel (pimecrolimus) cream 1%: a non-steroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol. 2003: 111: 1154–1168.
Pimecrolimus: a review of preclinical and clinical data. Int J Clin Pract 2003: 57: 319–327.
et al. Pimecrolimus: an ascomycin macrolactam derivative for the oral treatment of psoriasis – efficacy, safety, pharmacokinetics and pharmacogenetics. J Invest Dermatol 2002: 119: 876–888.DOI: 10.1046/j.1523-1747.2002.00694.x
Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect. J Invest Dermatol 2003: 121 (1): 391[Abstract]., ,
et al. Treatment with oral pimecrolimus significantly improves atopic dermatitis (AD) with a clear dose-response effect. J Invest Dermatol 2003: 121 (1): 1240[Abstract]., ,
et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999: 141: 264–273.DOI: 10.1046/j.1365-2133.1999.02974.x
Effect of pimecrolimus, tacrolimus, cyclosporin A, betamethasone 17-valerate, dexamethasone and hydrocortisone on cytokine production and T cell proliferation induced in human peripheral blood mononuclear cells. J Invest Dermatol 2003: 121 (1): 1225[Abstract]., , ,
Pimecrolimus inhibits upregulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin Exp Immunol 2002: 130: 85–92.DOI: 10.1046/j.1365-2249.2002.01962.x
Mast cells in allergy and beyond. Int J Biochem Cell Biol 2003: 35: 1601–1607.DOI: 10.1016/S1357-2725(03)00208-5
, , ,
Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998: 290: 501–507.DOI: 10.1007/s004030050343
, , , , ,
et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001: 108: 275–280.DOI: 10.1067/mai.2001.116865
Antigen-presenting cells. In: BieberT, LeungD Y, eds. Atopic Dermatitis. Basel: Marcel Dekker AG, 2002: 267–283.
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002: 23: 445–449.DOI: 10.1016/S1471-4906(02)02281-0
Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003: 133: 350–359.
, , ,
Grabbe. Effects of pimecrolimus on dendritic cell. J Invest Dermatol 2003: 121 (1): 1224[Abstract].DOI: 10.1046/j.1523-1747.2003.12550_5.x
, , ,
Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001: 107: 345–352.DOI: 10.1067/mai.2001.112600
, , ,
et al. In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression. Transplantation 2004: 19: 553–560.
Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. J Allergy Clin Immunol 2004: 114: 137–143.DOI: 10.1016/j.jaci.2004.03.021
, , , ,
Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003: 149: 853–857.DOI: 10.1046/j.1365-2133.2003.05559.x
, , , ,
Pimecrolimus, tacrolimus, cyclosporine A and corticosteroids: effects on human T cell activation in vitro. J Eur Acad Dermatol Venereol 2003: 17 (Suppl. 3): 353.
, , ,
Pimecrolimus does not affect cytokine and chemokine secretion and adhesion molecule expression in primary human keratinocytes and dermal fibroblasts. J Invest Dermatol 2003: 121 (1): 1243[Abstract]., ,
Side effects of potent topical corticosteroids. Can Med Assoc J 1978: 118: 173–174.
Side effects of topical corticosteroids and their prevention. Drugs 1988: 36 (Suppl. 5): 15–23.
Adverse effects of topical corticosteroid use. West J Med 1995: 162: 123–126.
Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med 2002: 60: 148–150.
New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol 2002: 3: 47–58.
Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004: 269: 29–35.
, , ,
et al. Pimecrolimus (Elidel®, SDZ ASM 981) cream 1% blood levels are consistently low in children with extensive atopic dermatitis (conference abstract). J Eur Acad Dermatol Venereol 2001: 15 (Suppl. 2): 109–110. , ,
et al. Systemic exposure, tolerability and efficacy of pimecrolimus 1% cream in atopic dermatitis patients. Arch Dis Child 2003: 86: 969–973.DOI: 10.1136/adc.88.11.969
Effect of percutaneous absorption of hydrocortisone and adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986: 115: 475–484.
, , , Systemic exposure of pimecrolimus cream 1% and tacrolimus ointment 0.1% in adult patients with moderate to severe atopic dermatitis. Poster presented at AAD, Washington, 6–11 February 2004.
Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992: 98: 851–855.DOI: 10.1111/1523-1747.ep12456939
Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int Arch Allergy Immunol 1992: 99: 486–489.
A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997: 137: 568–576.
, , , , ,
Pimecrolimus (SDZ ASM 981) cream equals tacrolimus (FK506) ointment in efficacy in porcine allergic contact dermatitis. Ann Dermatol Venereol 2002: 129: 1S701. ,
et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: a randomised, double-blind controlled study. Br J Dermatol 2001: 144: 507–513.DOI: 10.1046/j.1365-2133.2001.04076.x
et al. SDZ ASM 981 is highly effective in animal models of skin inflammation, but has only low activity in models indicating immunosuppressive potential, in contrast to cyclosporin A and FK 506. J Invest Dermatol 2001: 117: 532.
Pimecrolimus (Elidel®, SDZ ASM 981) – preclinical pharmacological profile and skin selectivity. Semin Cutan Med Surg 2001: 20: 233–241.
Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporin A. J Invest Dermatol 2003: 121: 77–80.DOI: 10.1046/j.1523-1747.2003.12331.x
Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 2000: 142: 669–679.DOI: 10.1046/j.1365-2133.2000.03411.x
et al. Cutaneous allergic contact dermatitis responses are diminished in mice deficient in neurokinin 1 receptors and augmented by neurokinin 2 receptor blockage. FASEB J 2004: 9: 1007–1009. , ,
Antipruritische Wirkung von Pimecrolimus und Tacrolimus. Hautarzt 2003: 54: 413–417.
Pimecrolimus induces neuropeptide release at early stages of topical application in vivo (conference abstract). IID, April 30 – May 4, 2003. J Invest Dermatol 2003: 121 (1): abstract 1248.
, , , , ,
The ascomycin derivatives ASM 981 (Pimecrolimus) and ASD 732 inhibit neuroinflammation in cutaneous hypersensitivity. Ann Dermatol Venereol 2002: 129: 1S330. , , , , ,
Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004: 122: 673–684.
, , , , ,
et al. Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunization. Toxicol Lett 2004: 149: 133–140.DOI: 10.1016/j.toxlet.2003.12.027
Pimecrolimus (SDZ ASM 981) has high affinity for the skin – a tissue distribution study in rats in comparison with tacrolimus (FK 506). Ann Dermatol Venereol 2002: 129: 1S704. , , ,
FKBP54, a novel FK506-binding protein in avian progesterone receptor complexes and HeLa extracts. J Biol Chem 1993: 268: 24270–24273.
, , , ,
NFAT signaling: choreographing the social life of cells. Cell 2002: 109: S67–S79.
et al. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporine A. J Biol Chem 1998: 273: 12378–12382.DOI: 10.1074/jbc.273.20.12378
et al. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. EMBO Rep 2000: 1: 428–434.DOI: 10.1093/embo-reports/kvd090
Pimecrolimus and tacrolimus differentially affect genes related to skin inflammation in rats. J Invest Dermatol 2003: 121 (1): 1192[Abstract]., , , ,
et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002: 110: e2.DOI: 10.1542/peds.110.1.e2
et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003: 142: 155–162.DOI: 10.1067/mpd.2003.65
FDA/Center for Drug Evaluation and Research. Elidel (pimecrolimus) cream. [Retrieved from http://www.fda.gov/cder/foi/nda/2001/21-302].
et al. Calcineurin inhibitors and skin cancer. J Invest Dermatol 2003: 121: 1072A. , ,
Pimecrolimus and tacrolimus show comparable potencies to inhibit the proliferation and cytokine synthesis of allergen-specific, atopic skin-derived T cell clones in vitro. J Invest Dermatol 2004: 122: A119.
, , , ,
In vitro penetration/permeation of pimecrolimus and tacrolimus from their marketed formulations (Elidel and Protopic). J Invest Dermatol 2004: 122: A40.
Pimecrolimus (SDZ ASM 981) and tacrolimus (FK 506) target skin and peripheral lymphoid organs differently in mice and rats. Ann Dermatol Venereol 2002: 129: 1S701. , , , , ,